argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.
ราคาปิดก่อนหน้า
US$925.7
−US$16.34 · -1.73%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.
ช่วงราคารายวัน
ปัจจุบัน US$925.7
ช่วง 52 สัปดาห์
ปัจจุบัน US$925.7
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ซื้อ
มูลค่า
81
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
71
เชิงบวก
ความเสี่ยง
28
ความเสี่ยงปานกลาง
โมเมนตัม
46
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.
ช่วงราคารายวัน
ปัจจุบัน US$925.7
ช่วง 52 สัปดาห์
ปัจจุบัน US$925.7
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 4.15B USD | 2.19B USD | 1.23B USD | 410.75M USD | 1.08B USD |
| ต้นทุนสินค้าขาย | 450.67M USD | 227.29M USD | 117.84M USD | 29.43M USD | 580.52M USD |
| กำไรขั้นต้น | 3.7B USD | 1.96B USD | 1.11B USD | 381.32M USD | 497.28M USD |
| การวิจัยและพัฒนา | 1.36B USD | 983.42M USD | 859.49M USD | 663.37M USD | 580.52M USD |
| การขาย ทั่วไป และธุรการ | 1.36B USD | 1.06B USD | 709.54M USD | 469.92M USD | 305.52M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 2.65B USD | 1.98B USD | 1.53B USD | 1.1B USD | 846.02M USD |
| รายได้ดอกเบี้ย | 163.09M USD | 138.5M USD | 92.96M USD | 24.74M USD | 3.49M USD |
| ดอกเบี้ยจ่าย | 4.08M USD | 2.22M USD | 904K USD | 2.19M USD | 1.1M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 28.1M USD | 17.53M USD | 111.31M USD | 104.34M USD | 5.87M USD |
| รายได้จากการดำเนินงาน | 1.05B USD | −21.65M USD | −425.05M USD | −720.34M USD | −348.75M USD |
| รายได้สุทธิ | 1.29B USD | 833.04M USD | −295.05M USD | −709.59M USD | −408.27M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 22 พ.ย. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$1,152.06
โอกาสปรับขึ้น 24.45%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
iShares Biotechnology ETFIBB398.08M3.80%10.53B USD0.44%US$199.54-2.05%
Capital Group Global Growth Equity ETFCGGO123.36M1.08%11.4B USD0.47%US$34.38-4.34%
First Trust NYSE Arca Biotechnology Index FundFBT110.86M3.87%2.87B USD0.55%US$257-2.20%
Avantis International Equity ETFAVDE29.97M0.16%18.31B USD0.23%US$82.46-2.61%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ25.39M1.99%1.2B USD0.48%US$32.48-3.39%
VanEck Biotech ETFBBH23.05M4.53%502.68M USD0.35%US$239.49-1.31%
Fidelity Enhanced International ETFFENI21.8M0.19%11.63B USD0.28%US$36.79-2.49%
Dimensional - International Core Equity Market ETFDFAI17.49M0.10%17.21B USD0.18%US$38.45-2.51%
iShares Biotechnology ETFIBB
Capital Group Global Growth Equity ETFCGGO
First Trust NYSE Arca Biotechnology Index FundFBT
Avantis International Equity ETFAVDE
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ
VanEck Biotech ETFBBH
Fidelity Enhanced International ETFFENI
Dimensional - International Core Equity Market ETFDFAIเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน